- Report
- December 2023
- 250 Pages
Global
€4841EUR$4,995USD£4,146GBP
- Report
- January 2024
- 216 Pages
United States
From €3634EUR$3,750USD£3,113GBP
- Report
- November 2020
- 260 Pages
Global
From €1333EUR$1,375USD£1,141GBP
€2665EUR$2,750USD£2,283GBP
- Drug Pipelines
- March 2022
- 162 Pages
Global
From €5524EUR$5,700USD£4,731GBP
- Report
- March 2022
- 324 Pages
Global
From €9207EUR$9,500USD£7,885GBP
- Report
- April 2023
- 115 Pages
Global
From €4603EUR$4,750USD£3,943GBP
From €3489EUR$3,600USD£2,988GBP
- Report
- May 2021
North America
From €1454EUR$1,500USD£1,245GBP
- Report
- July 2023
- 104 Pages
Global
From €3500EUR$3,869USD£3,103GBP
- Report
- July 2023
- 132 Pages
Global
From €921EUR$950USD£789GBP
- Report
- November 2021
- 600 Pages
Global
From €3876EUR$4,000USD£3,320GBP
- Report
- January 2023
- 235 Pages
Global
From €5553EUR$5,730USD£4,756GBP
Patient Controlled Analgesia (PCA) is a form of analgesic therapy that allows patients to self-administer medication to manage their pain. It is typically used in the hospital setting, and involves the patient using a device to deliver a predetermined dose of medication when needed. The device is programmed to deliver a certain amount of medication over a certain period of time, and the patient can press a button to receive an additional dose if needed. This allows the patient to have more control over their pain management, and can help reduce the risk of opioid-related side effects.
The PCA market is a subset of the analgesics market, and is growing as more healthcare providers recognize the benefits of this type of therapy. Companies in this market include Baxter International, B. Braun Melsungen AG, Fresenius Kabi, Hospira, and Smiths Medical. Show Less Read more